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Abstract 
 
An increasing number of studies indicate that serine proteases play an important role 
in structural plasticity associated with learning and memory formation. Neurotrypsin 
is a multidomain serine protease located at the presynaptic terminal of neurons. It is 
thought to be crucial for cognitive brain functions. A deletion in the neurotrypsin gene 
causes severe mental retardation in humans. For a biochemical characterization, we 
produced murine neurotrypsin recombinantly in a eukaryotic expression system using 
myeloma cells. From the culture medium we purified neurotrypsin using heparin-, 
hydrophobic interaction- and immobilized metal affinity chromatography. For an 
enzymological characterization two fragments of agrin containing the natural 
cleavages sites of neurotrypsin were used as substrates. The highest catalytic activity 
of neurotrypsin was observed in the pH range between 7.0 and 8.5. Calcium ions were 
required for neurotrypsin activity and an ionic strength exceeding 500 mM decreased 
substrate cleavage. Site-specific mutations of the amino acids flanking the scissile 
bonds showed that cleavage is highly specific and requires a basic amino acid 
preceded by a glutamate residue on the N-terminal side of the scissile bond. This 
sequence requirement argues for a unique substrate binding pocket of neurotrypsin. 
This observation was further substantiated by the fact that almost all tested serine 
protease inhibitors except Dichloroisocoumarin and PMSF did not affect neurotrypsin 
activity. 
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Introduction 
Neurotrypsin is a member of the serine protease family S1A. The murine ortholog 
of neurotrypsin consists of 761 amino acids with a molecular mass of 84 kDa and a 
theoretical pI of 8.6. It consists of a signalpeptide (SP), a proline-rich basic (PrB) 
region, a kringle (Kri) domain, three scavenger receptor cystein rich (SRCR) 
domains, and a serine protease (Prot) domain. The protease domain comprises 244 
amino acids and exhibits a 40% amino acid identity with trypsin. A zymogen 
activation site at the N-terminus of the protease domain bears the furin recognition 
sequence RRQKR. Murine neurotrypsin has three N-glycosylation site motives, one 
in the proline-rich basic domain and two in the protease domain [1]. In contrast to the 
rodent form of neurotrypsin, the human form exhibits an additional SRCR domain, 
which is conserved over all primates. The protease domain of murine and human 
neurotrypsin exhibit an amino acid identity of 89.9%. The overall amino acid 
sequence identity between murine and human neurotrypsin is 82.5 % [2]. 
In mice, expression of neurotrypsin is predominantly found in the brain [1, 3, 4], 
the kidney [3], and the lung [1, 3]. In situ mRNA hybridization on adult mouse brain 
sections revealed most prominent expression of neurotrypsin mRNA in the cerebral 
cortex, the subicular complex, the Ammon’s horn, the dentate gyrus, and the lateral 
amygdala [4]. Upregulation of neurotrypsin RNA is found in many brain regions 
especially in the hippocampus, neocortex, and the midbrain during pre- and postnatal 
development of the central nervous system [4]. Immunoelectron microscopic studies 
showed an association of neurotrypsin with the presynaptic membrane and the 
presynaptic active zone [5]. 
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Neurotrypsin plays an indispensible role for adaptive synaptic processes that are 
required for cognitive functions. A 4 base-pair deletion in the human neurotrypsin 
gene, which results in a truncated form of neurotrypsin lacking the protease domain, 
was identified as the cause of a severe form of mental retardation [6]. Recent studies 
identified the proteoglycan agrin as the so far unique proteolytic target of 
neurotrypsin, and demonstrated that neurotrypsin-dependent cleavage of agrin occurs 
at two homologous and highly conserved cleavage sites [3]. Live imaging studies 
demonstrated that both translocation of vesicular neurotrypsin to presynaptic nerve 
terminals and synaptic exocytosis of neurotrypsin are stimulated by neuronal activity 
[7]. Preparation of synaptosomes by subcellular fractionation and differential 
centrifugation and comparison of agrin and neurotrypsin-dependent agrin fragments 
in neurotrypsin-overexpressing and neurotrypsin-deficient mice indicated 
neurotrypsin-dependent cleavage of agrin as a process that is located at the synapse 
[7]. By local cleavage of the synapse-regulating proteoglycan agrin, neurotrypsin may 
be crucial for adaptive synaptic functions, such as the reorganization of synapses and 
neuronal circuits, which are required to establish and/or maintain higher cognitive 
functions. 
This study describes the expression of full-length murine neurotrypsin in myeloma 
cells and its purification. It further provides an initial characterization of murine 
neurotrypsin that allowed to set-up an in vitro activity assay. 
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Materials and methods 
Materials 
 
The chromatography resins were all purchased from GE Healthcare. The secondary 
antibodies HRP-conjugated anti-rabbit and anti-goat were from Sigma-Aldrich. The 
4-12% NuPAGE gels were from Invitrogen. SYPRO Ruby was from Molecular 
Probes, USA. 
 
Generation of neurotrypsin-specific antibodies 
 
Goat antiserum G87 was raised against the recombinant protease domain of human 
neurotrypsin (CAA04816), produced in E.coli. The goat antiserum G86 was generated 
against the SRCR domains 1-4 of human neurotrypsin antigen, produced in E.coli. 
Goat antiserum G93 was raised against full-length murine neurotrypsin (CAA73646) 
produced in stably transfected mouse myeloma J558L cells. Rabbit antiserum SZ177 
was raised against two synthetic peptides of the proline-rich basic segment 
corresponding to amino acids 22-40 and 45-57 of mouse neurotrypsin. Rabbit 
antiserum R89 was raised against the kringle domain of human and rat neurotrypsin 
(CAC35028), produced in E.coli. 
 
Cloning of full-lengh neurotrypsin for expression in myeloma cells 
 
For expression of neurotrypsin in myeloma cells, the coding region of full-length 
murine neurotrypsin (CAA73646) ranging from Met1 to Ser761, was inserted via the 
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restriction sites SacI and HindIII into the pCD4-FvCD3-c vector [8]. This mammalian 
expression vector comprises an immunoglobuline Vκ promotor and an 
immunoglobuline κ enhancer. For positive selection the vector included a histidinol 
resistance gene [9].  
 
Large-scale production of recombinant murine neurotrypsin in myeloma cells 
 
The protoplast fusion of the neurotrypsin expression vector and the murine myeloma 
cells was done as described previously [10] [11]. To achieve individual transfectants, 
the cells were diluted in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal calf serum (FCS, Biochrom AG, Germany) and plated 
in 96-well microtiter plates (PTT, Switzerland). Two days after transfection, cells 
with an insertion of neurotrypsin were selected by additional 5 mM L-histidinol to the 
growth medium (Sigma-Aldrich). Supernatants of surviving clones were analyzed for 
expression by Western blotting using the anti-neurotrypsin antibody SZ177. Clones 
with neurotrypsin expression were subcloned by limiting dilution for three rounds of 
single cell dilution. Briefly, cells were diluted and transferred into a 96-well 
microtiter plate to a calculated density of 0.5 cells per well. After 10-14 days in 
culture in presence of 5 mM L-histidinol the supernatants were again tested for 
neurotrypsin expression. Finally the best expressing clone was chosen for the large-
scale production of murine neurotrypsin. 
 
Adaptation of the neurotrypsin-expressing clones to protein-free medium 
 
 7 
Starting from a medium composed of DMEM (Sigma-Aldrich) containing 4 mM L-
glutamine and 10% FCS, the cells were adapted stepwise to grow in DMEM medium 
supplemented with 1% FCS. Adaptation was performed in 24-well plates (Nunc, 
Denmark) and the medium was exchanged every second day. When a density of about 
1x106 cells/ml was reached, cells were transferred into a new well with a density of 
3x105 cells/ml. Adapted cells growing in DMEM containing 1% FCS with a cell-
doubling time of around 18 h were then transferred to the serum-free but protein-
containing medium HL-1 (BioWhittaker Inc., USA) supplemented with 0.5% FCS. In 
HL-1 medium the cells were then stepwise adapted to grow in HL-1 medium without 
FCS. Finally the HL-1 medium was stepwise exchanged from 0% to 50%, to 90%, to 
98%, to 99.5% and finally to 100% by the protein-free medium TP-6 (Cell Culture 
Technology, Switzerland). The cells were maintained for neurotrypsin expression in 
rollerbottles (Greiner Bio-One, Belgium) rotating at 2 rpm in humidified incubaters at 
37° C and 10% CO2. 
 
Chromatographic purification of murine neurotrypsin  
 
For the purification of recombinant neurotrypsin, 14 L culture supernatant were 
concentrated using a Minisette tangential filtration cassette (Pall Corporation, USA). 
The retentate (500ml) was adjusted to pH 8.0 by the addition of 20mM Bis-Tris. 
Ammonium sulphate (Sigma-Aldrich) was added in small portions to a final 
saturation of 25% and afterwards stirred for 45 min at 4° C. The solution was 
centrifuged for 30 min at 24000 g. The pellet was discarded whereas the supernatant 
was subjected to another round of ammonium sulphate precipitation (a final saturation 
of 45%). After addition of the ammonium sulphate the pH of the solution was 
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adjusted to 8.0 and once more stirred for 45 min at 4° C. The solution was centrifuged 
and the pellet was resuspended in 200 ml loading buffer of the first chromatographic 
step. The resuspended protein was loaded onto a 60 ml heparin sepharose CL-B6 
column equilibrated with the loading buffer (50 mM NaCl, 0.1% PEG6000 in 20 mM 
MOPS, pH 6.8). The column was washed with one column volume of loading buffer 
substituted with 100 mM NaCl and bound proteins were eluted in a gradient of three 
column volumes from 100 mM to 1 M NaCl in loading buffer. Fractions of the late 
peak shoulder of the elution at NaCl concentration of around 600 mM were pooled. 
For the HIC column 1 M NaCl was added to the neurotrypsin fractions. After 
dissolving, the sample was loaded onto a 12 ml butyl sepharose column equilibrated 
with 1 M NaCl, 0.1% PEG6000 in 20 mM MOPS, pH 6.8. Bound proteins were 
eluted in three column volumes with a gradient from 1.25 M NaCl, 0.1% PEG6000 in 
20 mM MOPS, pH 6.8 to 0.1% PEG6000, 20 mM MOPS in 30% ethylenglycol, pH 
7.0. The neurotrypsin containing fractions were pooled, supplemented with 10 mM 
imidazole, and loaded onto a 1 ml column of copper-labeled chelating sepharose 
column equilibrated with 0.25 M NaCl, 10 mM imidazole, 0.1% PEG6000 in 20 mM 
MOPS, pH 7.0. Proteins were eluted in eight column volumes with a gradient from 10 
to 250 mM imidazole, 0.25 M NaCl, 0.1% PEG6000 in 20 mM MOPS, pH 7.0. All 
purification steps were performed on an Aekta Purifier Chromatography System (GE 
Healthcare). 
The concentration of neurotrypsin in the pooled fractions was determined by 
measuring the absorption at 280 nm with a CARY 50 spectrometer and calculated 
using the specific extinction coefficient for murine neurotrypsin of 159280 M-1 cm-1. 
Aliquots of 50 µl were frozen in liquid nitrogen and stored at -80° C. 
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Immunodetection of neurotrypsin 
 
Purified neurotrypsin (1.8 µg) was analyzed with 10% SDS-PAGE under reducing 
and non-reducing conditions. Electrotransfer was performed with semi-dry blotting 
apparatus. The immunodetection was done with the antibodies G93 (1:10'000 
diluted), G86 (1:3'000), G87 (1:5'000) and SZ177 (1:2'000). 
 
Two in vitro substrates for neurotrypsin 
 
α-Agrin bearing the α-cleavage site and β-agrin including the β-cleavage site served 
as substrates for cleavage assays with neurotrypsin. α-Agrin enclosed the rat agrin 
sequence (P25304 splice variant y4) from Lys51-Val1752 with the signal sequence of 
human calsyntenin-1 (Met1-Asn32 of NP_001009566) at the N-terminus, an N-
terminal 8x His-tag and a fused EGFP at the C-terminus. β-Agrin encoded the region 
Leu1528-Pro1959 of rat agrin including the signal sequence of human calsyntenin-1 and 
an N-terminal 8x His-tag. Both sequences were inserted into the PEAK8 vector 
(EdgeBio Systems, USA) and transiently transfected into HEK-293EBNA cells using 
PEI [12]. After 3-4 days of expression the culture supernatants were harvested. For 
purification of the recombinant protein the culture medium was replaced by loading 
buffer of the first chromatographic step by dialysis and cross-flow filtration, 
respectively. For the purification of α-agrin 2 L culture supernatant were concentrated 
and equilibrated with loading buffer by cross-flow filtration (Minimate TFF capsule, 
Pall corporation, USA). The retentate was loaded onto a HisSelect column (Sigma-
Aldrich) in 400 mM NaCl, 20 mM imidazol, 0.1% PEG 6000 in 20 mM phosphate pH 
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8.0. After extensive washing the bound proteins were eluted in a gradient of seven 
column volumes from 20 mM up to 250 mM imidazol. The α-agrin positive fractions 
were pooled and loaded on a MonoQ column equilibrated with 400 mM NaCl, 0.1% 
PEG 6000 in 20 mM sodium phosphate pH 8.0. Proteins were eluted in a step gradient 
of 2 M NaCl. The final Superdex 200 gelfiltration carried out in 150 mM NaCl, 0.1% 
PEG in 20 mM MOPS, pH 7.0. For the purification of β-agrin about 500 ml culture 
supernatant were dialysed against the loading buffer of the HisSelect column. The 
single chromatography step, performed as for the α-agrin, yielded sufficiently pure β-
agrin. The yield for α-agrin was up to 0.5 mg protein per 1 L culture supernatant, for 
β-agrin up to 5 mg protein per 1 L culture supernatant were obtained. All 
chromatographic steps were performed on an Aekta Purifier Chromatography System 
(GE Healthcare). 
 
 
In vitro activity assays for neurotrypsin 
 
If not otherwise indicated, in vitro digestions were carried out as follows: 
neurotrypsin (0.025 µM) was incubated with either α-agrin (0.6 µM) or β-agrin (1 
µM) for 1 h at 37°C in a buffer containing 150 mM NaCl, 5 mM CaCl2, 0.1% 
PEG6000 in 20 mM MOPS, pH 7.0. Assay samples were taken and the enzymatic 
reaction was stopped with 5x SDS-PAGE-sample-buffer containing EDTA (10% 
SDS, 30% glycerol, 0.6 M DTT, 100 mM EDTA, 0.35 M Tris, pH 6.8). The products 
of α-agrin were separated on 12% self-casted gels, the β-agrin product on 4-12% 
NuPAGE gels. The gels were stained with SYPRO Ruby (Molecular Probes, USA) 
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and quantified by fluorescent densitometry using the imaging system LAS-3000 and 
the AIDA software (both Fujifilm, Japan). 
 
Neurotrypsin broadband and selective inhibitor assay 
 
The broadband serine protease inhibitors AEBSF, aprotinin, TLCK (all Roche 
Diagnostics, Switzerland), benzamidine (Acros Organics), 3,4-Dichloroisocoumarin 
(DCI), leupeptin and PMSF (all Sigma-Aldrich) were tested at the concentrations 
indicated in table 3. Neurotrypsin (0.025 µM) was preincubated with different 
inhibitors for 40 min before addition of β-agrin (1 µM). The reactions were stopped 
after 45 min, the proteins were separated on 4-12% NuPAGE gels and were 
quantified using densitometry. As control trypsin (5 nM) (Sigma-Aldrich) and the 
chromogenic substrate S-2222 (500 µM) (Chromogenix Instrumentation Laboratory 
S.p.A., USA) were used. The slope of the absorption of the increasing S-2222 product 
signal was measured for all inhibitors at 405 nm for 5 min using the Victor3 plate 
reader (Perkin Elmer, USA) and compared to the measured slope of the not inhibited 
reaction. 
The specific inhibitors Pefablock PL, Pefablock uPA, Pefablock Try, Pefablock TH 
(all from Pentapharm, Switzerland) were dissolved in DMSO and tested at a 
concentration of 150 µM with 0.025 µM neurotrypsin and 1 µM β-agrin. The 
reactions were stopped after 90 min. Product formation was investigated using SDS-
PAGE and densitometry. The control experiment was performed on target enzymes 
with inhibitor concentrations 20 times higher than the corresponding Ki value. The 
slope of the absorption values of the increasing product was measured at 405 nm for 5 
min using a CARY 50 spectrometer (VARIAN). Thrombin (750 nM) (Merck) was 
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incubated with BzFVRpNA (17 µM) (Bachem), trypsin (20 nM) (Sigma-Aldrich) 
with 2 µM S-2222, factor Xa (70 µM) (Sigma-Aldrich) with 100 µM S-2288 
(Chromogenix Instrumentation Laboratory S.p.A.), urokinase (120 nM) (Sigma-
Aldrich) with BzVGRpNA (20 µM) (Sigma-Aldrich), and plasmin (90 nM) (Sigma-
Aldrich) was incubated with 425 µM S-2288. 
 
Assessment of the substrate preference of neurotrypsin with mutated agrin 
substrates 
 
For activity measurements neurotrypsin (0.025 µM) was incubated with β-agrin (0.3 
µM) or α-agrin (0.6 µM). At time points between 0 and 360 min for β-agrin and 0 and 
120 min for α-agrin, samples were taken and the reaction was immediately stopped 
by adding SDS-PAGE-sample-buffer containing EDTA. The β-agrin cleavage 
products were separated in 4-12% NuPAGE gels and the α-agrin products in 12% 
self-casted SDS-PAGE gels. Afterwards the gels were stained with SyproRUBY and 
quantified by densitometry. Initial velocities were determined by linear regression in 
the early phase of the progress curve. Pseudo first-order rate constants were 
determined by fitting the integrated Michaelis-Menten equation ([Pt] = [P∞] (1-exp(-k 
t))+c, whereas Pt reflected the product concentration at timepoint t, P∞ is the product 
concentration at complete turn-over, k reflects the rate constant and c is a correction 
factor) to the whole progress curve of product release. Calculations were performed 
with the SigmaPlot 9.0 software. 
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Results and discussion 
Expression of recombinant murine neurotrypsin in myeloma cells 
 
The full-length form of murine neurotrypsin was recombinantly expressed in a 
myeloma cell-based expression system, because several attempts for producing active 
neurotrypsin by other expression systems have failed. In brief, we expressed the 
protease domain as inclusion bodies in E. coli and refolded it. We also expressed the 
protease domain combined with the flanking SRCR domain into the periplasmatic 
space of E. coli. Both approaches did not result in active neurotrypsin. Likewise, the 
expression attempts of full-length neurotrypsin, as well as the isolated protease 
domain in HEK-293T, HEK-293EBNA cells, in Pichia Pastoris, and with the 
baculovirus expression system failed. For the stable expression, the coding region 
comprising the amino acids Met1-Lys761 was engineered under the control of a κ light 
chain promotor into a vector that was specially designed for expression in myeloma 
cells [8]. This vector construct was introduced into J558L myeloma cells by 
protoplast fusion [11]. Positive selection for neurotrypsin gene integration into the 
myeloma cells was obtained with the aid of L-histidinol. Out of 5x106 cells of the 
protoplast fusion, 60 clones survived selection. These clones were analyzed for 
neurotrypsin expression by Western blotting with the neurotrypsin specific antibody 
SZ177. Three of the surviving clones showed neurotrypsin expression and were 
subjected to three further rounds of subcloning. To facilitate the subsequent 
purification of neurotrypsin, the best expressing clone was then stepwise adapted to 
the protein free medium TP-6 and subsequently maintained in suspension culture in 
roller bottles. The concentration of recombinant neurotrypsin in the supernatant 
reached approximately 0.5 µg/ml, as determined on Western blots by comparison 
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with a dilution series from a known concentration of purified neurotrypsin. 
 
Purification of murine neurotrypsin 
 
For the purification of recombinant neurotrypsin from the culture supernatant of 
myeloma cells a five-step protocol was established. Initially, 14 L culture 
supernatants were concentrated by cross-flow filtration. The retentate was precipitated 
at 45% saturation of ammonium sulphate. The highly basic nature of the N-terminal 
proline-rich basic segment suggested a binding of neurotrypsin to heparin. The 
obtained pellet was resuspended in the loading buffer of the heparin affinity column, 
the first chromatography step. Neurotrypsin was bound to the heparin matrix in a 
buffer containing 50 mM NaCl and eluted in a gradient to 1 M NaCl. Late elution 
fractions of the heparin affinity purification were collected (Fig. 1a). The heparin 
purification step separated 97% of the contaminating proteins. With the first step a 
purification factor of 48 and a yield of 28% was achieved. For the following 
hydrophobic interaction chromatography (HIC), 1 M NaCl was added to the pooled 
neurotrypsin-containing fractions and the sample was loaded onto the butyl sepharose 
column. Proteins were eluted from the HIC matrix with a buffer containing 30% 
ethylenglycol (Fig. 1b). The HIC purification increased the purification factor 18-fold, 
while the overall yield after this step was 17%. In the final step an immobilized metal 
affinity chromatography (IMAC) column labelled with copper ions was used. 
Unspecific binding of proteins was suppressed by adding 10 mM imidazol to the 
loading buffer. Pure neurotrypsin was eluted in a gradient to 250 mM imidazol (Fig. 
1c). Over-all, 0.6 mg neurotrypsin were obtained from 14 L conditioned TP-6 culture 
supernatant with a purification factor of 2104 and a yield of 8 % (table 1). On the 
 15 
silver stained gel under reducing conditions 1.8 µg purified neurotrypsin protein 
appeared as nine distinct bands as shown in figure 2b. These results indicated that 
expression of full-length neurotrypsin in our expression system was followed by 
several steps of partial proteolytic processing. 
All nine fragments were subjected to Edman degradation. N-terminal sequences 
could be determined for seven fragments. The sequences identified all bands as 
components of murine neurotrypsin (figure 2b and 3). Sequencing of the faintest band 
migrating at 69.8 kDa (*4) and of the blurred band at 58.0 kDa (*5) failed. These 
bands were identified as neurotrypsin derivatives based on their imunoreactivity with 
three antibodies directed against different domains of neurotrypsin. Thus, all the nine 
fragments visible on the silver stained gel could be assigned to murine neurotrypsin 
(Fig. 2b). The apparent Mr of band *4 and its recognition by the antibodies G93 and 
G87 suggests that this fragment spans from Val107 (located in the kringle domain) to 
Arg662 (located in the protease domain) and is glycosylated at both predicted sites for 
N-linked oligosaccharides in the protease domain of typically ~4 kDa (Fig. 3). The 
band *5 is detected by the antibodies G93, G86 and SZ177 and therefore most likely 
represents the non-catalytic domain of neurotrypsin of theoretical 54.8 kDa bearing 
the predicted N-glyosylation in the proline-rich basic segment. Thus, this fragment 
ranges from the N-terminus of native neurotrypsin, Asp23, to the zymogen activation 
site, Arg516 (Fig. 3). The discrepancy of the calculated molecular masses and the 
determined masses in the SDS-PAGE gel of fragment 3 might be due to an 
incomplete glycosylation. The activated protease domain, cleaved at the predicted 
zymogen activation site (between Arg516-Ile517 as confirmed by N-terminal 
sequencing), migrates with an apparent molecular mass of 33.3 kDa on a 10% SDS-
PAGE gel under reducing conditions. This band is recognized only by the 
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neurotrypsin specific antibody directed against the protease domain (G87) and by the 
antibody against the full-length neurotrypsin (G93). Furthermore, the N-terminal 
sequencing of the full-length band confirmed the predicted cleavage site of the signal 
peptide, which lies between Ala20 and Asp21. SDS-PAGE analysis of the purified 
neurotrypsin under non-reducing conditions showed two major bands and three minor 
bands when silver stained. All these bands could be also detected with the two 
antibodies G86 and G87 directed against the neurotrypsin SRCR domains and the 
protease domains, respectively (Fig. 2c) 
To measure the ratio between the zymogenic single- and the activated two-chain 
neurotrypsin, we used the protease domain-specific antibody G87 for Western 
blotting under reducing conditions (Fig. 2b - G87). This antibody was assumed to 
yield equivalent immunoreactivity signals for the isolated band of 33.5 kDa 
representing the two-chain form of neurotrypsin (marked by asterisk) and the catalytic 
domains associated with the single-chain forms of neurotrypsin (marked by circle). 
Based on densitometric quantifications of these bands on Western blots our 
preparations contained 50% of the neurotrypsin in single chain form and 50% in two-
chain form.  
 
Enzymological characterization of neurotrypsin 
 
We used β-agrin as a substrate to assess the effects of pH, calcium, and ionic 
strength on neurotrypsin activity (Fig. 4). Six different buffer systems (sodium acetate 
- pKa 4.7, MES - pKa 6.1, PIPES - pKa 6.8, MOPS - pKa 7.2, BICIN - pKa 8.3, and 
AMPSO - pKa 9.0) covering the pH range between 4.0 and 10.0 were used for the 
determination of pH dependency of neurotrypsin. We found that Neurotrypsin started 
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to cleave its substrate at pH 5.5 and its activity increased continuously until maximal 
activity was reached at pH 8.5. At pH values higher than 9.0 the activity declined 
rapidly (Fig. 4b). In the cationic BICIN buffer neurotrypsin activity was considerably 
lower than in the other buffers. Calcium dependence was tested at concentrations 
between 0 and 20 mM. To ensure that no calcium was bound to enzyme or substrate, 
10 mM EDTA was added to the 0 mM sample. We found that calcium is essential for 
neurotrypsin activity, with half maximal substrate turnover at a concentration of 0.45 
mM. Maximal activity was found between 5 and 10 mM calcium (Fig. 4c). The ion 
strength-dependence of neurotrypsin was studied with a series of increasing 
concentrations of NaCl. In the range of 50 to 200 mM NaCl neurotrypsin activity was 
not affected. At NaCl concentrations above 500 mM the catalytic efficiency dropped 
significantly (Fig. 4d). Based on these results we composed the buffer for in vitro 
assays: 150 mM NaCl, 5 mM CaCl2, 0.1% PEG 6000 in 20 mM MOPS, pH 7.0.  
The effects of pH, calcium, and NaCl on neurotrypsin activity were also assessed 
with the highly glycosylated α-agrin as substrate (Fig. 4e-g). For the determination of 
the pH dependence sodium acetate, MES, MOPS, and AMPSO were chosen. 
Neurotrypsin started to cleave α-agrin at pH 5.5 and activity was highest between pH 
7.0 and 8.5. At basic pH values, higher than 9.0, the activity declined rapidly (Fig. 
4e). A calcium concentration of 0.85 mM was required for half maximal substrate 
turnover, compared to 0.45 mM for β-agrin. Maximal activity was reached at 
approximately 10 mM CaCl2 (Fig. 4f). Cleavage of α-agrin was less sensitive to ionic 
strength than cleavage of β-agrin (Fig. 4g). Maximal neurotrypsin activity was 
reached between 50 and 200 mM NaCl concentration, whereas higher concentrations 
resulted in a rapid decrease in activity. 
A pseudo first-order rate constant for the cleavage of β-agrin of 4.7 x 10-4 s-1 was 
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determined by fitting the integrated Michaelis-Menten equation to the experimental 
data (Fig. 5). The pseudo first-order rate constant k obtained in this way corresponds 
to the V/Km ratio, where V represents the limiting rate. Dividing this rate constant by 
the titrated enzyme concentration yields the kinetic constant kcat/Km, defining the 
catalytic efficiency. Unfortunately, an active site titrant for neurotrypsin was not 
available. Based on our gel analysis we estimated that 50% (25 nM) of the purified 
neurotrypsin was in the activated two-chain form, while 50% was in the zymogenic 
single-chain form (Fig.2b - G87). Therefore, the catalytic efficiency kcat/Km was 1.9 x 
104 M-1 s -1. The discrepancy between the k-values of the substrate consumption and 
the product formation for the α-agrin in figure 5c is due to the quantification of the 
indistinct highly glycosylated N-terminal product signals in the gel. Because of the 
partial overlap of substrate and forming N-terminal product, we based our 
measurements on the formation of the C-terminal product fragment, which migrated 
well isolated on the SYPRO Ruby stained gels.  
 
Inhibition of neurotrypsin activity by commercial serine protease inhibitors 
 
The cleavage of β-agrin by neurotrypsin was used to evaluate the effect of four 
selective inhibitors of serine proteases and seven broadband serine protease inhibitors. 
Selective inhibitors against thrombin, trypsin, plasmin and urokinase were used at a 
concentration of 150 µM, which was at least 180 times higher than the Ki determined 
for their cognate target protease. In control experiments with chromogenic substrates, 
at inhibitor concentrations 20 times higher than the indicated Ki, all the target 
proteases showed 10% or less residual activity. As shown in table 2, none of the 
specific inhibitors had an effect on neurotrypsin activity. 
 19 
The effects of seven broadband inhibitors of serine proteases were tested at two 
concentrations. The higher concentration used for the reversible inhibitors 
benzamidine, leupeptin, aprotinin and for the initially reversible inhibitor TLCK was 
at least 20 times higher than their corresponding Ki determined for trypsin. The 
preincubation time for the irreversible inhibitors PMSF, AEBSF, and DCI was chosen 
at least 10 times longer than the half-life referred to kobs/[I] values for trypsin. In a 
control experiment the integrity of the inhibitors was verified for trypsin using a 
chromogenic substrate. As summarized in table 3, the proteolytic activity of 
neurotrypsin was almost completely inhibited by the irreversible inhibitors PMSF (0.5 
mM) and DCI (0.1 mM). Benzamidine a common competitive inhibitor for trypsin-
like serine proteases had only a poor inhibitory effect. In contrast, leupeptin, 
aprotinin, AEBSF and TLCK did not affect neurotrypsin activity at the tested 
concentrations at all. 
 
Neurotrypsin exhibits high substrate specificity 
 
Wild-type α- and β-agrin together with the mutants bearing single amino acid 
exchanges to alanine at P5 to P1 of the α and at P4 to P1 of the β cleavage sites were 
used to assess the specificity of murine neurotrypsin. We also analyzed the mutation 
from the P1 lysine to arginine and the mutation from P1 arginine to lysine in the α- 
and β cleavage site, respectively. In addition, we swapped the recognition sequences 
between the cleavage sites. For both substrates the turnover of each mutant was 
analyzed in time course experiments. For quantification, the products were collected 
after increasing reaction times, separated by SDS-PAGE, and stained with SYPRO 
Ruby. Rate constants for β-agrin were determined by a first order kinetic analysis. 
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Fitting the exponential curve to the product data revealed a rate constant of 4.7 x 10-4 
s-1. The results are summarized in figure 6a. There was no substrate processing with 
an alanine at the position P1 and the catalytic efficiency was reduced 40-fold when 
the glutamate at the P2 site was mutated to alanine. Mutations of P3 and P4 reduced 
the substrate turnover to 44% and 54%, respectively. The P1 mutation from lysine to 
arginine and the replacement of the cognate recognition sequence of the β site by the 
α recognition sequence resulted in a minor increase of the catalytic efficiency to 
130% and 144%, respectively, compared to wild-type. We also calculated the initial 
velocities of the P site mutants of β-agrin. We found the same substrate preference as 
with the rate constants (data not shown). 
Due to uncertainties in the progress curves, it was not possible to determine single 
rate constants for the much larger and highly glycosylated α-agrin mutants. However, 
the determined initial velocities indicated the same kinetic changes after 
corresponding amino acid substitutions at both cleavage sites (Fig. 6b). α-Agrin with 
an alanine mutation at position P1 was not cleavable. An alanine replacing the 
glutamate at the P2 site resulted in a residual activity of 6%. Alanine mutations at P3, 
P4 and P5 in α-agrin had a similar impact on murine neurotrypsin activity and 
decreased activity to 19%, 23% and 25%. Substitution of the arginine at the P1 site by 
lysine decreased neurotrypsin activity to 70%. 
 
 
 
 
Conclusion 
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This work reports on the expression and the purification of active recombinant murine 
neurotrypsin. Based on enzymological characterizations, optimized conditions for in 
vitro assays were worked out. Highest neurotrypsin activity was found at a pH 
between 7.0 and 8.5, an ionic strength of around 150 mM and calcium ions at 
concentrations between 5 and 10 mM. The optimum conditions found for in vitro 
assays are in good accordance with the physiological working environment of the 
neurotrypsin in the extracellular space at the synapse [5, 7]. 
Alanine-scanning of the P1 to P5 amino acids of both cleavage sites confirmed the 
strict dependence of neurotrypsin activity on the basic P1 residue, as expected from a 
serine protease exhibiting a aspartate residue at position 189. A strong reduction of 
proteolyic activity was also observed by mutagenesis of the glutamic acid residue at 
P2. The relatively large effect of the glutamate to alanine mutation of this site is 
consistent with the strict evolutionary conservation of both neurotrypsin-dependent 
cleavage sites of agrin [3]. Only the irreversible serine protease inhibitors PMSF and 
DCI showed an inhibitory effect on neurotrypsin, while all of the other tested serine 
protease inhibitors were completely ineffective. These results indicate a narrow 
specificity of neurotrypsin. 
The determined catalytic efficiency of neurotrypsin (kcat/KM 1.9x104 M-1s-1) is 
comparable to that of other extracellular trypsin-like serine proteases with a 
regulatory function. For example thrombin cleaves protease-activated receptor 4 with 
an catalytic efficiency of 2.8x105 M-1s-1 [13] or tissue-type plasminogen activator 
cleaves plasminogen with a kcat/KM of 9.5x103 M-1s-1 [14]. 
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Figure legends 
 
Figure 1: Elution profiles of neurotrypsin chromatography: (a) heparin column, (b) 
HIC column, (c) IMAC column. Horizontal bars indicate collected fractions. Solid 
line indicates the absorption at 280 nm and the dotted line the percentage of buffer B. 
 
Figure 2: Purity of recombinant neurotrypsin after chromatography. (a) Domain 
structure of murine neurotrypsin. PB, proline-rich basic domain; KR, kringle domain; 
SRCR1 to SRCR3, scavenger receptor cysteine-rich domains 1 to 3; ZA, zymogen 
activation region; PROT, serine protease domain; circles, putative N-glycosylation 
sites. Horizontal bars indicate the domains used as immunogenes for the production of 
the different antibodies. SDS-PAGE of 1.8 µg protein under reducing conditions (b) 
and under non-reducing conditions (c). Numbers in (b) refer to N-terminal sequencing 
in figure 3. The bands marked by a circle and a triangle on the Western blot shown in 
(b) represent the single-chain and the catalytic domain of the two-chain form, 
respectively. The signal intensities of these bands were used to determine the ratio of 
single-chain to two-chain neurotrypsin in our preparations. (d) Amino acid sequence 
of mouse neurotrypsin showing the N-termini of the purified enzyme. The vertical 
arrows indicate the N-terminal sites of fragments 1 - 3 and 6 – 9. Amino acids 
obtained by N-terminal sequencing are printed in bold type. Catalytic residues of the 
protease domain are depicted in white. 
 
Figure 3: Analysis of neurotrypsin fragments. The neurotrypsin fragments identified 
on the Western blots of purified neurotrypsin were mapped to the domain structure of 
murine neurotrypsin based on their N-terminal sequence, their apparent Mr, and their 
reactivity with different antibodies. Horizontal bars indicate the extensions of the 
neurotrypsin fragments. Abbreviations are as in figure 2. 
 
Figure 4: Schematic drawings of the protein substrates β-agrin and α-agrin (a) each 
having a cleavage site for neurotrypsin, indicated by the arrow. Enzymological assays 
with purified β-agrin (b-d) and α-agrin (e-g) as substrate. (b) pH profile of 
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neurotrypsin activity. Neurotrypsin showed highest activity between 7.0 and 8.5. All 
buffers were 100 mM: acetate for pH 4.0-5.5; MES for pH 5.5-6.5; PIPES pH 6.0-7.0; 
MOPS for pH 6.5-8.0; BICINE pH7.5-9.0; AMPSO for pH 8.0-10.0. (c) Calcium 
dependence of neurotrypsin. (d) Influence of ionic strength. (e) pH profile of 
neurotrypsin activity. Neurotrypsin showed highest activity between 7.0 and 8.5. All 
buffers were 100 mM: acetate for pH 4.0-5.5; MES for pH 5.5-6.5; MOPS for pH 6.5-
8.0; AMPSO for pH 8.0-10.0. (f) Calcium dependence of neurotrypsin. (g) Influence 
of ionic strength. Bars indicate standard deviation of at least three replicates. FS - 
cysteine-rich repeat similar to follistatin; LE - laminin EGF-like domain; S/T - 
serine/threonine-rich region; SEA - sperm protein, enterokinase, and agrin domain; 
EG - epidermal growth factor (EGF)-like domain; LG - laminin globular domain; 
single circles - sites of N-linked glycosylation; multiple circles - sites of glycan 
attachment. 
 
Figure 5: Time course of neurotrypsin-dependent cleavage of agrin, (a) cleavage of 
α-agrin and (b) β-agrin visualized by SDS-PAGE using SYPRO Ruby. The signal 
intensities of product (open circles) and the substrate (black circles) were plotted and 
pseudo first-order rate constants were determined; ks, rate constant for substrate 
consumption and kP, rate constant for product formation. 
 
Figure 6: Cleavage site mutagenesis reveals high dependence on a basic residue at P1 
and a glutamic acid at P2. (a) Alanine scan of β-agrin from P4 to P1, Lys to Arg 
mutation at P1 (K/R), and the replacement of P3 to P2’ by the sequence of the α-
cleavage site (α/β). (b) Alanine scan of α-agrin from P4 to P1, Lys to Arg mutation at 
P1 (K/R). 
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Table 1
Purification profile of neurotrypsin
volume 
[ml]
total protein 
[mg]
protein 
[mg/ml]
neurotrypsin 
[mg]
neurotrypsin 
[mg/ml]
purification 
factor
conc. supernatant 200 240.0 1.22 7.5 0.038 -
heparin column 90 7.5 0.08 2.1 0.023 48
butyl column 24 1.3 0.06 1.3 0.055 867
IMAC column 4 0.5 0.13 0.6 0.15 2104
Table 2
Effect of specific serine protease inhibitors on the activity of purified neurotrypsin
inhibitor inhibited 
protease
Ki of spec. 
protease
conc. [μM] residual activity of 
neurotrypsin %
residual activity of 
targeted enzyme 
% a
none - - - 100 ± 2.8 -
Pefabloc Tyr1405 Trypsin 0.02 μM 0.12 108 ± 7.8 10.5 ± 3.3
Pefabloc TH Thrombin 0.006 μM 0.12 113 ± 10.4 7.8 ± 0.1
Pefabloc uPA uPA 0.54 μM 10.8 115 ± 8.1 8.6 ± 1.5
Pefabloc Pl Plasmin 0.14 μM 2.8 108 ± 8.6 10.1 ± 3.4
a obtained at an inhibitor concentration 20x larger than Ki
Table 3
Effect of broadband serine protease inhibitors on the activity of purified neurotrypsin
inhibitor concentration 
[mM]
residual activity of 
neurotrypsin %
residual activity of 
trypsin %
none - 100 ± 13.3 100 ± 2.8
benzamidine 1
10
96.4 ± 2.0
75.0 ± 3.6
11.5 ± 0.3
3,4-dichloro-isocoumarin 0.1
1
15.7 ± 0.7
2.4 ± 0.5
5.4 ± 0.6
leupeptin 0.01
0.1
98.8 ± 4.3
101.8 ± 3.9
5.1 ± 0.5
PMSF 0.05
0.5
41.0 ± 7.8
1.5 ± 3.3
3.4 ± 1.3
TLCK 0.3
3
102.8 ± 2.4
100.1 ± 0.9
7.0 ± 0.3
AEBSF 0.1
1
116.6 ± 3.3
110.2 ± 3.3
< 1.0
Aprotinin 0.01
0.1
118.3 ± 0.1
127.1 ± 3.4
< 1.0
